Aclaris Therapeutics, Inc. $ACRS Shares Purchased by Braidwell LP

Posted by on Sep 3rd, 2026

Braidwell LP increased its stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report) by 26.1% during the 2nd quarter, Holdings Channel.com reports. The fund owned 2,142,348 shares of the biotechnology company’s stock after buying an additional 443,232 shares during the period. Braidwell LP’s holdings in Aclaris Therapeutics were worth $11,333,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Sei Investments Co. purchased a new stake in shares of Aclaris Therapeutics during the 1st quarter valued at $814,000. Kalehua Capital Management LLC purchased a new position in shares of Aclaris Therapeutics in the 1st quarter worth $6,871,000. Dimensional Fund Advisors LP boosted its holdings in Aclaris Therapeutics by 88.8% in the first quarter. Dimensional Fund Advisors LP now owns 511,461 shares of the biotechnology company’s stock valued at $1,914,000 after acquiring an additional 240,611 shares during the last quarter. Deutsche Bank AG purchased a new stake in Aclaris Therapeutics during the second quarter valued at about $5,507,000. Finally, Monashee Investment Management LLC purchased a new stake in Aclaris Therapeutics during the first quarter valued at about $1,875,000. Institutional investors and hedge funds own 98.34% of the company’s stock.

Aclaris Therapeutics Price Performance

Shares of ACRS stock opened at $6.18 on Thursday. The firm has a fifty day moving average of $5.72 and a two-hundred day moving average of $4.64. The firm has a market cap of $864.09 million, a P/E ratio of -10.66 and a beta of 0.79. Aclaris Therapeutics, Inc. has a 1-year low of $1.74 and a 1-year high of $6.60.

Aclaris Therapeutics (NASDAQ:ACRS – Get Free Report) last issued its quarterly earnings results on Thursday, August 6th. The biotechnology company reported ($0.15) EPS for the quarter, topping the consensus estimate of ($0.16) by $0.01. Aclaris Therapeutics had a negative net margin of 921.50% and a negative return on equity of 61.65%. The business had revenue of $1.63 million for the quarter, compared to analysts’ expectations of $1.38 million. On average, sell-side analysts expect that Aclaris Therapeutics, Inc. will post -0.65 EPS for the current year.

Analyst Ratings Changes

A number of research firms recently issued reports on ACRS. Canaccord Genuity Group initiated coverage on shares of Aclaris Therapeutics in a research report on Tuesday. They set a “buy” rating and a $10.00 target price for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aclaris Therapeutics in a research note on Wednesday, June 24th. Lifesci Capital started coverage on shares of Aclaris Therapeutics in a research report on Tuesday, June 2nd. They issued an “outperform” rating and a $13.00 price objective for the company. Finally, Wall Street Zen upgraded shares of Aclaris Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, May 16th. Three analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Aclaris Therapeutics presently has a consensus rating of “Buy” and an average price target of $11.33.

Get Our Latest Stock Analysis on Aclaris Therapeutics

Aclaris Therapeutics Profile

(Free Report)

Aclaris Therapeutics, Inc (NASDAQ:ACRS) is a clinical‐stage biopharmaceutical company focused on discovering, developing and commercializing novel small‐molecule therapies for dermatologic diseases and related rare disorders. The company’s pipeline includes several product candidates designed to address chronic inflammatory skin conditions and non‐melanoma skin lesions. Lead programs include ATI‐50002, a topical agent in late‐stage development for molluscum contagiosum removal; ATI‐50003 for common wart resolution; ATI‐1501, an oral JAK1/2 inhibitor targeting pruritic disorders; and ATI‐450, an oral MK2 inhibitor for inflammatory indications.

Founded in 2016 and headquartered in Malvern, Pennsylvania, Aclaris leverages proprietary chemistry platforms and translational research capabilities to advance multiple clinical and preclinical candidates.

See Also

Want to see what other hedge funds are holding ACRS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aclaris Therapeutics, Inc. (NASDAQ:ACRS – Free Report).

Institutional Ownership by Quarter for Aclaris Therapeutics (NASDAQ:ACRS)

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.